Mycrodose Therapeutics
Mycrodose Therapeutics is a San Diego-based biotech developing advanced drug delivery systems for psychedelic and controlled-substance therapeutics. One of only a few companies with DEA Schedule I research licences covering psilocybin, LSD, MDMA, and DMT, the company has demonstrated in vitro delivery of psilocin through human skin using a proprietary transdermal patch technology. A second programme involves an oral mucosa delivery system for ketamine targeting cancer-related mucositis. Mycrodose has completed an oversubscribed private placement to expand its patent portfolio.
Drug Pipeline
2Psilocybin transdermal patch
PsilocybinTransdermal patch delivering psilocin; in vitro pre-clinical studies demonstrated successful delivery through human skin at both macro and microdose levels.
Ketamine oral mucosa delivery
KetamineOral mucosa (lozenge) delivery system for ketamine; initially targeting cancer-related mucositis.
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Pre-clinical
- Website
- Visit